Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18945306rdf:typepubmed:Citationlld:pubmed
pubmed-article:18945306lifeskim:mentionsumls-concept:C0027651lld:lifeskim
pubmed-article:18945306lifeskim:mentionsumls-concept:C0035820lld:lifeskim
pubmed-article:18945306lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:18945306lifeskim:mentionsumls-concept:C0026948lld:lifeskim
pubmed-article:18945306lifeskim:mentionsumls-concept:C0034790lld:lifeskim
pubmed-article:18945306lifeskim:mentionsumls-concept:C0521447lld:lifeskim
pubmed-article:18945306lifeskim:mentionsumls-concept:C0002199lld:lifeskim
pubmed-article:18945306lifeskim:mentionsumls-concept:C0016072lld:lifeskim
pubmed-article:18945306lifeskim:mentionsumls-concept:C0040649lld:lifeskim
pubmed-article:18945306lifeskim:mentionsumls-concept:C1704259lld:lifeskim
pubmed-article:18945306lifeskim:mentionsumls-concept:C0683598lld:lifeskim
pubmed-article:18945306lifeskim:mentionsumls-concept:C1705987lld:lifeskim
pubmed-article:18945306pubmed:issue1lld:pubmed
pubmed-article:18945306pubmed:dateCreated2009-1-9lld:pubmed
pubmed-article:18945306pubmed:abstractTextInterferon (IFN)-alpha is widely used in the treatment of mycosis fungoides (MF) and when used in combination with photochemotherapy (psoralen plus ultraviolet A, PUVA) both improved response and duration of complete remission have been reported. However, in spite of encouraging results of the initial studies, currently there is no information available on specific prognostic factors enabling prediction of patients' resistance to PUVA +/- IFN-alpha treatment.lld:pubmed
pubmed-article:18945306pubmed:languageenglld:pubmed
pubmed-article:18945306pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18945306pubmed:citationSubsetIMlld:pubmed
pubmed-article:18945306pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18945306pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18945306pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18945306pubmed:statusMEDLINElld:pubmed
pubmed-article:18945306pubmed:monthJanlld:pubmed
pubmed-article:18945306pubmed:issn1365-2133lld:pubmed
pubmed-article:18945306pubmed:authorpubmed-author:AlvarezMMlld:pubmed
pubmed-article:18945306pubmed:authorpubmed-author:VidalSSlld:pubmed
pubmed-article:18945306pubmed:authorpubmed-author:MontesSSlld:pubmed
pubmed-article:18945306pubmed:authorpubmed-author:Rodriguez-Per...lld:pubmed
pubmed-article:18945306pubmed:authorpubmed-author:PirisM AMAlld:pubmed
pubmed-article:18945306pubmed:authorpubmed-author:FragaJJlld:pubmed
pubmed-article:18945306pubmed:authorpubmed-author:Fernández...lld:pubmed
pubmed-article:18945306pubmed:authorpubmed-author:Ortiz-RomeroP...lld:pubmed
pubmed-article:18945306pubmed:authorpubmed-author:TraceyLLlld:pubmed
pubmed-article:18945306pubmed:authorpubmed-author:WozniakM BMBlld:pubmed
pubmed-article:18945306pubmed:authorpubmed-author:Villuendas...lld:pubmed
pubmed-article:18945306pubmed:issnTypeElectroniclld:pubmed
pubmed-article:18945306pubmed:volume160lld:pubmed
pubmed-article:18945306pubmed:ownerNLMlld:pubmed
pubmed-article:18945306pubmed:authorsCompleteYlld:pubmed
pubmed-article:18945306pubmed:pagination92-102lld:pubmed
pubmed-article:18945306pubmed:meshHeadingpubmed-meshheading:18945306...lld:pubmed
pubmed-article:18945306pubmed:meshHeadingpubmed-meshheading:18945306...lld:pubmed
pubmed-article:18945306pubmed:meshHeadingpubmed-meshheading:18945306...lld:pubmed
pubmed-article:18945306pubmed:meshHeadingpubmed-meshheading:18945306...lld:pubmed
pubmed-article:18945306pubmed:meshHeadingpubmed-meshheading:18945306...lld:pubmed
pubmed-article:18945306pubmed:meshHeadingpubmed-meshheading:18945306...lld:pubmed
pubmed-article:18945306pubmed:meshHeadingpubmed-meshheading:18945306...lld:pubmed
pubmed-article:18945306pubmed:meshHeadingpubmed-meshheading:18945306...lld:pubmed
pubmed-article:18945306pubmed:meshHeadingpubmed-meshheading:18945306...lld:pubmed
pubmed-article:18945306pubmed:meshHeadingpubmed-meshheading:18945306...lld:pubmed
pubmed-article:18945306pubmed:meshHeadingpubmed-meshheading:18945306...lld:pubmed
pubmed-article:18945306pubmed:meshHeadingpubmed-meshheading:18945306...lld:pubmed
pubmed-article:18945306pubmed:meshHeadingpubmed-meshheading:18945306...lld:pubmed
pubmed-article:18945306pubmed:meshHeadingpubmed-meshheading:18945306...lld:pubmed
pubmed-article:18945306pubmed:meshHeadingpubmed-meshheading:18945306...lld:pubmed
pubmed-article:18945306pubmed:meshHeadingpubmed-meshheading:18945306...lld:pubmed
pubmed-article:18945306pubmed:meshHeadingpubmed-meshheading:18945306...lld:pubmed
pubmed-article:18945306pubmed:meshHeadingpubmed-meshheading:18945306...lld:pubmed
pubmed-article:18945306pubmed:meshHeadingpubmed-meshheading:18945306...lld:pubmed
pubmed-article:18945306pubmed:meshHeadingpubmed-meshheading:18945306...lld:pubmed
pubmed-article:18945306pubmed:year2009lld:pubmed
pubmed-article:18945306pubmed:articleTitlePsoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways.lld:pubmed
pubmed-article:18945306pubmed:affiliationMolecular Pathology Program, Centro Nacional de Investigaciones Oncológicas, Madrid, Spain.lld:pubmed
pubmed-article:18945306pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18945306pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:18945306pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18945306lld:pubmed